80
Participants
Start Date
January 7, 2025
Primary Completion Date
July 31, 2026
Study Completion Date
October 31, 2026
Hypericin
HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Placebo
Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
RECRUITING
Columbia University Medical Center, New York
RECRUITING
Rochester Skin Lymphoma Medical Group, Fairport
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Penn State Health Hershey Medical Center, Hershey
RECRUITING
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
Inova Schar Cancer Institute, Fairfax
RECRUITING
Accellacare (PMG), Wilmington
RECRUITING
University of South Florida, Tampa
RECRUITING
Vanderbilt University, Nashville
RECRUITING
Dawes Fretzin Dermatology Group, Indianapolis
RECRUITING
Northwestern University, Chicago
RECRUITING
Washington University, St Louis
RECRUITING
MD Anderson, Houston
RECRUITING
Austin Institute for Clinical Research, Pflugerville
RECRUITING
Medical Dermatology Specialists, Phoenix
RECRUITING
Mayo Clinic, Scottsdale
RECRUITING
Therapeutics Clinical Research, San Diego
Lead Sponsor
Soligenix
INDUSTRY